998 resultados para Neoplasias da mama-etnologia
Resumo:
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Resumo:
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Resumo:
Pós-graduação em Medicina Veterinária - FMVZ
Resumo:
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Resumo:
Pós-graduação em Medicina Veterinária - FMVZ
Resumo:
Pós-graduação em Ginecologia, Obstetrícia e Mastologia - FMB
Resumo:
Pós-graduação em Medicina Veterinária - FCAV
Resumo:
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Resumo:
Pós-graduação em Medicina Veterinária - FMVZ
Resumo:
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Resumo:
Breast cancer has received an increasing attention because it is one of the most common cancer type and a leading cause of morbity and mortality among women worldwide. This disease has been considered as a heterogeneous condition, demonstrating a large spectrum of clinical and histopathological variability. In the last two decades, several studies have been conducted to identify new molecular markers of cancer cells, including the alterations of DNA methylation, which is the major epigenetic mechanism associated with the control of gene expression. The hypermethylation of promoter-associated CpG islands contributes to the loss of function of several cancer-related genes, including those encoding to the estrogen receptor (ESR) and progesterone receptor (PGR). This study aimed to determine the methylation patterns of CpG islands of the genes encoding the estrogen receptor α (ESR1 gene, promoters A and B), estrogen receptor β (ESR2 gene) and progesterone receptor (PGR gene, promoter A and B) in 15 cell lines derived from breast cancer. The DNA methylation analysis was based on the “Methylation Specific-Polymerase Chain Reaction” (MSP), which provides a qualitative assessment of the methylation status of a specific CpG island. The results revealed heterogeneous data: the promoter region of ESR1A showed complete methylation in one cell line (BT549) and only two cell lines showed partial methylation (MDA-MB-231 and MDA-MB-453), while the others lineages presented unmethylated alleles. The promoter region of isoform ESR1B was unmethylated in the cell lines BT549, SKBR3 and T47D; partial methylation were observed in the cell lines MDA-MB- 231, MCF-7 and ZR-75-30, while the others cell lines presented complete methylation. All lineages showed complete or partial methylation of the ESR2 gene. The methylation pattern of the promoter A of the PGR ...(Complete abstract click electronic access below)
Resumo:
Pós-graduação em Patologia - FMB
Estudo com familiares de pacientes com câncer de mama: abordando conhecimento sobre fatores de risco
Resumo:
Breast cancer (BC) is the most common malignancy in women worldwide, with one million new cases confirmed each year. This study aimed at identifying the knowledge of patients? relatives concerning the risk factors (RF) for BC. It is a descriptive quantitative study carried out in the Chemotherapy Technical Division of a University Hospital in São Paulo state, Brazil, from September to October 2006. Only female (30) relatives were included due to the fact that BC is more frequent in females. The major RF cited were family history for BC 33.3% (10), smoking 16.6% (5), alcoholic-drink consumption 10% (3), animal-fat-rich diet 3.3% (1). Other factors such as not breastfeeding, environmental factors, use of oral contraceptives and hormone-replacement therapy were mentioned by 10% (3) of the relatives. It was concluded that the relatives of patients undergoing chemotherapeutic treatment showed to have little knowledge concerning RF for BC. Hence, it is important to rethink the inclusion of the health education process in the family scenario. This issue reaches far beyond thesimple transmission of information. Healthcare professionals and nurses in particular, must focus on these individuals? social context, values, beliefs and needs.
Resumo:
Fil: Roqué, María. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Laboratorio de Biología Celular y Molecular IHEM-CONICET CCT.
Resumo:
A nivel mundial, el cáncer mamario representa el 23% de las enfermedades oncológicas que afectan a las mujeres. En el año 2008 fue responsable de 458.400 muertes. Las probabilidades de curar a una paciente dependen del avance de la enfermedad en el momento del diagnóstico. La estimación del pronóstico y predicción del tratamiento de las pacientes es fundamental para el manejo clínico de la enfermedad. La metástasis en ganglios linfáticos, el tamaño y el grado tumoral son los factores pronóstico más importantes, mientras que la expresión de los receptores de estrógeno, progesterona y del factor de crecimiento epidérmico 2 son marcadores para la predicción de la respuesta a distintos tratamientos. Las células tumorales presentan un genoma y un epigenoma distinto a las células normales. La alteración epigenética mejor entendida y más estudiada es la metilación aberrante de genes reguladores del ciclo celular. Esta tesis doctoral tiene como objetivo identificar las alteraciones epigenéticas relacionadas con el cáncer de mama humano. Para ello el trabajo ha sido dividido en tres bloques. El primero, centrado en el estudio de las alteraciones epigenéticas de la carcinogénesis mamaria. El segundo, enfocado en establecer relaciones entre las alteraciones epigenéticas y los aspectos clínicos de la enfermedad. El tercero, enfocado en la detección no invasiva de procesos oncológicos en las pacientes. Esta tesis muestra los resultados del análisis de la metilación aberrante de 49 regiones del genoma involucradas en el desarrollo de enfermedades oncológicas. El estudio ha permitido determinar el perfil de metilación tumoral de 92 tumores mamarios invasores, 17 melanomas, 8 hepatoblastomas y 6 tumores de próstata. Las alteraciones en la metilación de estos genes es específica para cada paciente y la información epigenética permite diferenciar el proceso tumoral mamario del resto de los tumores. La cantidad y el tipo de genes afectados correlacionan con factores de mal pronóstico y factores que predicen respuesta a tratamientos. Las células que escapan a los ganglios mantienen la metilación aberrante del tumor primario, rasgo que ha servido para detectar ADN tumoral circulando en la sangre de las pacientes con la enfermedad. Los resultados aportan a un mejor entendimiento del proceso tumoral mamario y al futuro diseño de estudios para la detección temprana y no invasiva de la enfermedad.